| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Net income | -8.0 | -4.4 |
| EPS (diluted, $ a share) | $-0.46 | $-1.41 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
10-Q filed with the SEC, NASDAQ: CLRB. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Cellectar Biosciences, Inc.: key numbers
- Share price
- $1.01Close, Nov 16
- Market cap
- $10.1M
- Shares outstanding
- 10.04MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Cellectar Biosciences, Inc.
All →Cellectar Biosciences Financial Results
Cellectar Biosciences reported financial results for the third quarter of 2026, highlighting progress toward a planned accelerated approval filing for iopofosine I 131 in Waldenström macroglobulinemia (WM). The company remains on track to file its NDA with the FDA in the first half of 2027 and expects to dose the first patients in its Phase 3 confirmatory trial in Q1 2027.
- Term
- Q3 2026
“We remain focused on executing the clinical, regulatory and operational activities necessary to position iopofosine I 131 for potential registration and commercialization in Waldenström macroglobulinemia, and we believe our third quarter progress represents a significant step toward that goal.”
James Caruso, president and chief executive officer of Cellectar Biosciences
“To further maximize the long-term value of the program, we have initiated our Phase 1b dosimetry trial, which we believe offers an important opportunity to further characterize iopofosine I 131 across WM treatment settings, including first and second line.”
James Caruso, president and chief executive officer of Cellectar Biosciences